eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
12 hedge funds and large institutions have $188M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 55 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
62% more capital invested
Capital invested by funds: $116M → $188M (+$72.1M)
79% less funds holding
Funds holding: 58 → 12 (-46)
84% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 55
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$62.2M |
| 2 |
CG
Column Group
San Francisco,
California
|
+$55.6M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$37.2M |
| 4 |
Blackstone Inc
New York
|
+$16.9M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$318K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$9.89M |
| 2 |
LA
Linden Advisors
New York
|
-$8.99M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$8.54M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.62M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$4.95M |
EFTR Hedge Fund Activity: Q3 2021 in Review
12 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q3 2021, worth a combined $188M — up 62% from $116M a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of EFTR and 9 opened new positions — a net loss of 46 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Abingworth, opening a new position worth an estimated $62.2M. The largest seller was Empyrean Capital Partners, exiting entirely with an estimated $9.89M sold.
- 12 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q3 2021, down from 58 in Q2 2021.
- Funds reported $188M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q3 2021, up 62% quarter-over-quarter.
- 9 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q3 2021 and 55 closed out, a net change of -46 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q3 2021 was Abingworth, an estimated $62.2M added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q3 2021 was Empyrean Capital Partners, an estimated $9.89M sold.
Based on aggregated 13F filings for Q3 2021.